Undervalued and Ready to Make a significant move up:
...a few facts you may wish to consider...
AVXT: AVAX Technologies, Inc. , the facts as I see them ... a viewpoint.
-"AVAX Poised to Become a Leading Individualized Cell and Gene Therapy Company."
-The autologous cancer vaccine has 55% survival rate (compared to 22% with no post surgical treatment,
and a survival rate of about 33% with a protocol of AlphaInterferon, the current "Gold Standard).
-Nine years of data; and all data was reported, nothing was deleted or held back at all.
-The vaccine is virtually NON TOXIC.
-Commercialized and selling cancer vaccine to patients in Australia, (patients will travel.)
-Australian market has the highest melanoma incidence in the world.
-Plans are in process to open up business soon in Netherlands. (by the end of 2001)
-Plans are in process to open up business soon in Germany. (by the end of 2001)
-Plans are in the works on doing business in Japan. (University of Tokyo is doing cancer trials for no cost!)
-Launch of MVAX in New Zealand planned soon!
-Very close to patent approval for the other 3 cancer fighting compounds. (O-VAX, B-VAX, L-VAX).
-The Company also anticipates development of similar technology for the treatment of other cancers, which
may include prostate, lung and colorectal cancer.
-Patent filings for the TOPOISMERASE INHIBITOR and cancer fighting ANTI-ESTROGEN COMPOUNDS expected.
-The company is planning a move to the national NASDAQ market this year.
-M-VAX blows away the current gold standard melanoma treatment, no contest imo.
-Genopoietic is now a Wholly Owned Subsidiary of AVAX Technologies, as of: 08/24/2000. biz.yahoo.com
-GENOPOIETIC recently in genetics news: "supplies RETROVIRAL VECTOR for bubble babies."
-AVAX has Acquired All Patent Rights from the Cell and Gene Therapy Laboratory of Dr. David
Klatzmann at UPMC avxtinvestors.homestead.com
-Genopoietic technologies are autologous chondrocytes for the repair of damaged cartilage AND thymidine kinase (TK) suicide gene
technology for the treatment of graft-versus-host-disease (GVHD), cancer and other indications.
-Genopoetic's primary products include therapies for joint repair, bone marrow transplantation, autoimmune
diseases and organ transplantation.
-PIPELINE: add the great AVXT pipeline to that of Genopoietics: that should make AVXT the global leader
in the personalized treatment field (13 products). 1:Cartilage repair ,2:joint repair, 3:bone marrow transplants,
4:auto immune deseases, 5:multiple sclerosis, 6:gene therapy for cancer, 7:organ transplants,
8:anticancer topoisomerase inhibitor compounds, 9:cancer fighting anti-estrogen compounds,
10:M-VAX for melonoma, 11:O-VAX for ovarian cancer, 12:L-VAX for leukemia, 13:B-VAX for breast
cancer.
-AVXT only a 180 million dollar MARKET CAP.
-CEO said in interview that he expects news on patent approvals for his 2 other cancer drugs.
-AVXT recently got 25 million dollars in a private placement so money is not a current issue.
-Expect to hear more on M-VAX sales; expect to hear more on O-VAX , B-VAX and L-VAX.
-M-Vax is in late stage trial, pivotal trial registration is the last stop before APPROVAL.
-There is no present competition to MVAX, according to Dr. Jonas in the 10K.
-Expect to hear a few more cancer applications for our vaccine (other types of cancer).
-SMALL MARKET CAP, HUGE PIPELINE (go ahead and compare it to others!).
-AVAX CEO stated they are looking aggessively into the possibility of doing the vaccine for earlier stage
patients too.
-The company stated there have been no regulatory inquiries or compliance concerns, zero, none.
-Start of clinical development of topoisomerase inhibitors planned for later this year.
-Start of clinical development in one additional cancer indication planned this year.
-Extension of M-VAX to earlier stage patients in progress through low-dose arm in current MM trial.
-Extension of M-VAX to patients in Stage 4 MM in progress.
-A five (5) year survival rate of patients over 50 was 71%, versus 47% for those under 50.
-Significantly longer 5-year survival rate of 71%, versus 49% for those who did not show the DTH
response(welt at injection spot).
-A total of 25 cancer trial sites available here in USA.
-AVAX Technoloigies, Inc. has three CORE TECHNOLOGIES: the AC Vaccine technology,
topoisomerase inhibitors and anti-estrogens.
-"Genopoietic enhances AVAX's pipeline of products within oncology and beyond, to include
therapies for joint repair, bone marrow transplantation, autoimmune diseases, such as multiple
sclerosis, and even organ transplantation." ~from SEC filing S-8.
-M-VAX has received ORPHAN DRUG STATUS IN THE U.S. The AC Vaccine technology is also
being evaluated in a multi-center Phase 2 trial in OVARIAN CANCER (O-Vax™), a Phase 1/2 equivalent
trial in BREAST CANCER with The University of Tokyo, and a Phase 1/2 trial in ACUTE
MYELOGENOUS LEUKEMIA (L-Vax™) at the MD Anderson Cancer Center. The AC Vaccine™
technology was invented by David Berd, M.D., professor of medicine at the Kimmel Cancer Center at
Thomas Jefferson University in Philadelphia.
-M-Vax is produced through a contract manufacturing agreement with Bioenterprises Pty. Ltd. for Australian
patients.
-Audio lecture by Dr. Berd (the inventor): avax-tech.com :AVAX Technologies,Inc.
-Develop and commercialize: it's acquired the exclusive worldwide rights to a series of compounds for the
potential treatment of cancer and other infectious diseases from Rutgers.
-The Company has acquired the exclusive worldwide rights to another series of compounds for the potential
treatment of cancer from Texas A&M.
-The Company leased a laboratory research facility in Albany, New York for advancing research on the AC
Vaccine technology.
If you need to verify any information the CEO doesn't mind chatting but will only talk about public info:
CEO: Jeffrey Jonas: (816) 960-1333.
stockhouse.com
:AVXT getting noticed.
messages.yahoo.com
:*****AVAX Tech. in this conf. on SEPTEMBER 18-19, 2000.******
biz.yahoo.com
:Announcement of GENOPOIETIC aquisition. |
